『Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time』のカバーアート

Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time

Keytruda: How Merck's Pembrolizumab Became the Best-Selling Cancer Drug of All Time

無料で聴く

ポッドキャストの詳細を見る
Keytruda is Merck's $31 billion a year PD-1 inhibitor and the best-selling cancer drug of all time. In Episode 3 of Approved, Alex Kesin and Matthew Pech trace the development of pembrolizumab , featuring interviews the scientists who drove the program forward : co-inventors Gregory Carven and Michel Streuli, and former Merck oncology CMO Roy Baynes.Topics include preclinical PD1 / CTLA-4 checkpoint biology that brought industry attention to the target (Jim Allison's CTLA-4 work and Tasuku Honjo's PD-1 discovery); how pembro started as a failed rheumatoid arthritis antibody program at a Dutch subsidiary of a paint company; the two mega-mergers that nearly killed the program; the biomarker enrichment trial design behind KEYNOTE-024 that let Merck break BMS's lead in lung cancer; the 41-patient Johns Hopkins MSI-H trial behind the first tissue-agnostic FDA approval, and the Jimmy Carter melanoma case that brought pembrolizumab to the public conscious. The episode closes on what comes next for Merck: the 2028 patent cliff, the Keytruda QLEX subcutaneous launch, and efforts to find the next blockbuster checkpoint inhibitor, including Summit/Akeso's PD-1 / VEGF bispecific ivonescimab.This episode is presented by JLL. Featuring Grant Dettmer on biotech real estate strategy.CHAPTERS 00:00:00 — Introduction: The Best-Selling Cancer Drug of All Time 00:02:15 — Part One — A Century of Failed Cancer Immunotherapy 00:04:17 — T Cells, CD28, and the Two-Signal Model of Immune Activation 00:06:25 — Jim Allison's CTLA-4 Discovery and the Path to Yervoy 00:12:03 — Tasuku Honjo Discovers PD-1: A Better Brake on T Cells 00:14:26 — Lieping Chen and the PD-L1 Tumor Evasion Hypothesis 00:16:26 — Part Two — Organon: The Dutch Paint-Company Subsidiary Behind Keytruda 00:19:48 — How Michel Streuli Caught the Solid-Phase Screening Artifact 00:22:09 — The Accidental Antagonist: From Rheumatoid Arthritis Drug to Cancer Drug 00:26:34 — Sponsor: Grant Detmer (JLL) on Biotech Real Estate Strategy 00:30:01 — Russian Nesting-Doll M&A: Schering-Plough Acquires Organon (2007) 00:31:43 — The $41 Billion Merck–Schering-Plough Mega-Merger of 2009 00:34:58 — Corporate Guerrilla Warfare: Four Scrappy Stunts That Saved Pembrolizumab 00:39:32 — BioNovion's Spite-Company Bid to Buy Pembro Back 00:42:10 — BMS at ASCO 2010: The Data Print That Revived Merck's PD-1 Program 00:45:55 — Part Three — Roger Perlmutter Joins a Bleeding Merck (April 2013) 00:50:48 — "Let Me Manage the Tigers": Ken Frazier Backs the All-In Bet on Pembrolizumab 00:55:22 — Breakthrough Therapy Designation and Eric Rubin's Adaptive Trial Design 00:58:25 — Keytruda's 2014 FDA Approval Erases BMS's Four-Year Lead 01:00:24 — The Lung Cancer Battlefield and the PD-L1 Biomarker Bet 01:02:19 — BMS vs. Merck: All-Comers vs. Biomarker-Enriched Trial Strategy 01:08:18 — KEYNOTE-024 vs. CheckMate-026: The Trial That Decided the Category 01:12:03 — Luis Diaz, MSI-H, and the Failed BMS Trial That Made Keytruda Tissue-Agnostic 01:17:18 — KEYNOTE-189: Perlmutter's Bet on Combining Keytruda with Chemotherapy 01:19:21 — Merck's Clinical Development Playbook: Basket Trials, Backwards March, External Collabs 01:25:29 — Part Four — The IO Graveyard: TIGIT, CD47, IDO1, LAG-3 and Tens of Billions Incinerated 01:30:23 — Why PD-1 Was the Only Checkpoint That Worked (Lieping Chen Revisited) 01:33:32 — Part Five — Inside the Best-Selling Drug of All Time 01:37:03 — "Build a Wall, High and Wide": Merck’s Commercial Strategy for Keytruda 01:43:44 — Part Six — The Patent Cliff and Loss of Exclusivity in Pharma 01:45:35 — Keytruda QLEX (Subcutaneous) and the Lifecycle Management Playbook 01:50:23 — PD-1/VEGF Bispecifics: Ivonescimab, Summit Therapeutics, and the Next Threat 01:55:31 — The Scorecard: Patient, Academic, and Financial Impact 02:01:19 — Who Actually Profited: Merck vs. Organon vs. the Scientists Who Built the Drug 02:05:54 — Epilogue: The Jimmy Carter DrugSourcesLast updated: May 2026Essential readingShaywitz, David. "The Startling History Behind Merck's New Cancer Blockbuster." Forbes, Jul 26, 2017. The definitive Organon-era origin story.Loftus, Peter. "Why Merck Is Betting Big on One Cancer Drug." WSJ, Apr 15, 2018. Source for Perlmutter's "whatever other projects you're working on, you can stop now."Lowe, Derek. "The Keytruda Story." In the Pipeline.Graeber, Charles. The Breakthrough. Twelve, 2018.Primary interviewsGreg Carven, Michel Streuli, Roy Baynes — Approved podcast interviews (2026). Quotes attributed to these speakers come from these conversations unless otherwise noted.Foundational scienceStutman. "Tumor development in athymic-nude mice." Science (1974). The flawed experiment that...
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません